ORIGINAL ARTICLE

Correlation between the level of urine interleukin-6 with microalbuminuria in Systemic Lupus Erythematosus (SLE) patients at Sanglah General Hospital, Bali, Indonesia

Yenny Kandarini, I Gusti Putu Hery Sikesa , Gede Kambayana

Yenny Kandarini
Nephrology and Hypertension Division, Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

I Gusti Putu Hery Sikesa
Residency of Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia. Email: bejo_udayana@yahoo.com

Gede Kambayana
Rheumatology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia
Online First: August 01, 2020 | Cite this Article
Kandarini, Y., Sikesa, I., Kambayana, G. 2020. Correlation between the level of urine interleukin-6 with microalbuminuria in Systemic Lupus Erythematosus (SLE) patients at Sanglah General Hospital, Bali, Indonesia. Bali Medical Journal 9(2): 516-519. DOI:10.15562/bmj.v9i2.1888


Background: Lupus Nephritis (LN) is one of the serious manifestations of SLE. Because of its role in the pathogenesis of LN, IL-6 is likely to be a potential marker, whereas for diagnosing kidney involvement at the subclinical stage, microalbuminuria can be examined. Therefore, early detection of kidney damage in SLE is needed to prevent the progression of NL to permanent kidney failure. This study aims to evaluate the relationship between IL-6 levels and microalbuminuria in SLE patients at Sanglah General Hospital Bali.

Methods: This study used a cross-sectional analytic design, carried out in Sanglah General Hospital on SLE patients, conducted in May until July 2019. Blood and urine samples were taken to obtain the data needed to measure the Mex-SLEDAI score. Cytokine evaluation is done by quantitative examination using enzyme-linked immunosorbent assay (ELISA). Chi-square analysis was done using SPSS version 24 for Windows.

Results: The results of the study were 85 subjects with SLE (94.1% women). The median age is 35 years (18-61 years), and the median duration of illness is three years (0.4-18 years). Most of the patients were in inactive clinical condition, 54 patients (63.53%) and laboratory results were still in the normal range. Steroids (94.1%) are the most widely used therapeutic options. Urine IL-6 levels were obtained with a mean of 0.41±0.21 pg/ml, while microalbuminuria levels were obtained with a median of 20 (0-100) mg/L. The results of data analysis stated that there was no significant relationship between urine IL-6 levels and microalbuminuria in SLE (p = 0.972).

Conclusion: In this study, there was no significant relationship between urine IL-6 levels and microalbuminuria.

References

Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25:727–734.

Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004; 13(5):339–343.

Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Díaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus. 1998;7(3):154–158.

Mogensen CE, Friedman C. Clinician’s Manual on Microalbuminuria. London: Current Medical Group. 2006.

Quintana LF dan Jayne D. Sustained remission in lupus nephritis: still a hard road ahead. Nephrol Dial Transplant. 2016;31: 2011–2018.

Wilhelmus S, Alpers CE, Cook HT, Ferrario F, Fogo AB, Haas M, et al. The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions. J. Am. Soc. Nephrol. 2015; 26(12):2938–2946.

Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin. Nephrol.1993;40:16–21.

Peterson E, Robertson AD, Emlen W. Serum and Urinary Interleukin-6 in Systemic Lupus Erythematosus. Lupus. 1996;5:571–575.

Dima A, Caraiola S, Jurcut C, Miler, I., Balanescu, P., Ramba, D., et al. Clinical Significance Of Serum And Urinary Interleukin-6 In Systemic Lupus Erythematosus Patients. Egypt. Rheumatol.. 2016.1-6.

El-Shereef RR , Lotfi A, Abdel-Naeam EA, Tawfik H. Serum and Urinary Interleukin-6 in Assessment of Renal Activity in Egyptian Patients with Systemic Lupus Erythematosus. Clin Med Insights Arthritis Musculoskelet Disord. 2016; 9: 29–36.

Swaak AJ, van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and Acute Phase Proteins in The Disease Course of Patients with Systemic Lupus Erythematosus. Rheumatol Int. 1989;8(6):263-8.

Familia AC, Yuliasih Y, Rahmawati LD. Correlation Between Serum Il-6 Level And Th17/Treg Ratio With Systemic Lupus Erythematosus Disease Activity. Biomol Health Sci. J. 2019;2(2):107-112.

Ceccarelli F, Cipriano E, Scavalli AS, Perricone C, Alessandri C, Novelli G, et al. Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. J. Immunol. Res. 2015:1-11.

Martadiani ED, Widiana IGR, Dewi DAR. Ultrasound evaluation of nephritis, hepatic steatosis, and knee joint effusion in Balinese women with systemic lupus erythematosus. Bali Med J. 2017;3(3): S1-S6.

Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron. 2000;85:207–14.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0